EA201992528A1 - Способы применения тризамещенных производных бензотриазола в качестве ингибиторов дигидрооротатоксигеназы - Google Patents

Способы применения тризамещенных производных бензотриазола в качестве ингибиторов дигидрооротатоксигеназы

Info

Publication number
EA201992528A1
EA201992528A1 EA201992528A EA201992528A EA201992528A1 EA 201992528 A1 EA201992528 A1 EA 201992528A1 EA 201992528 A EA201992528 A EA 201992528A EA 201992528 A EA201992528 A EA 201992528A EA 201992528 A1 EA201992528 A1 EA 201992528A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trizosmitted
digydroorotatoxygenase
benzotriazole
inhibitors
derivatives
Prior art date
Application number
EA201992528A
Other languages
English (en)
Inventor
Кавита Неллоре
Субраманиа Хосахалли
Original Assignee
Ориджин Дискавери Текнолоджиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/899,707 external-priority patent/US20180369206A1/en
Application filed by Ориджин Дискавери Текнолоджиз Лимитед filed Critical Ориджин Дискавери Текнолоджиз Лимитед
Publication of EA201992528A1 publication Critical patent/EA201992528A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В данном изобретении представлены способы лечения рака у субъекта и ингибирования роста опухоли, метастазов или активности фермента дигидрооротатоксигеназы в опухоли или раковой клетке. По меньшей мере одно тризамещенное производное бензотриазола формулы (I)вводят субъекту или вводят в контакт с раковой клеткой. Соединения формулы (I) имеют заместители R, Rи R, которые имеют значения, данные в описании, и их фармацевтически приемлемые соли.
EA201992528A 2018-02-20 2018-04-19 Способы применения тризамещенных производных бензотриазола в качестве ингибиторов дигидрооротатоксигеназы EA201992528A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/899,707 US20180369206A1 (en) 2017-04-24 2018-02-20 Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
PCT/IB2018/052710 WO2018197997A1 (en) 2017-04-24 2018-04-19 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Publications (1)

Publication Number Publication Date
EA201992528A1 true EA201992528A1 (ru) 2020-02-28

Family

ID=65803213

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992528A EA201992528A1 (ru) 2018-02-20 2018-04-19 Способы применения тризамещенных производных бензотриазола в качестве ингибиторов дигидрооротатоксигеназы

Country Status (26)

Country Link
US (1) US20220241246A1 (ru)
EP (2) EP3915557A1 (ru)
JP (2) JP7225114B2 (ru)
KR (1) KR20190140005A (ru)
CN (1) CN110662539B (ru)
AU (1) AU2018260390B2 (ru)
BR (1) BR112019022331A2 (ru)
CA (1) CA3060390A1 (ru)
CY (1) CY1124702T1 (ru)
DK (1) DK3615027T3 (ru)
EA (1) EA201992528A1 (ru)
ES (1) ES2889100T3 (ru)
HR (1) HRP20211462T1 (ru)
HU (1) HUE056485T2 (ru)
IL (1) IL270066B2 (ru)
LT (1) LT3615027T (ru)
MA (1) MA48459B1 (ru)
MD (1) MD3615027T2 (ru)
MX (1) MX2019012640A (ru)
PH (1) PH12019502402A1 (ru)
PL (1) PL3615027T3 (ru)
PT (1) PT3615027T (ru)
RS (1) RS62519B1 (ru)
SG (1) SG11201909718QA (ru)
SI (1) SI3615027T1 (ru)
TW (1) TWI821180B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016929A8 (pt) * 2018-02-20 2022-06-28 Agios Pharmaceuticals Inc Métodos de uso para derivados de benzotriazol trissubstituídos
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494911A (en) 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
ES2882797T3 (es) 2009-04-02 2021-12-02 Merck Serono Sa Inhibidores de dihidroorotato deshidrogenasa
PT3019482T (pt) * 2013-02-25 2018-11-28 Aurigene Discovery Tech Ltd Derivados de benzotriazole trissubstituídos enquanto inibidores de di-hidro-orotato-oxigenase

Also Published As

Publication number Publication date
PH12019502402A1 (en) 2021-01-25
RS62519B1 (sr) 2021-11-30
US20220241246A1 (en) 2022-08-04
JP2020517654A (ja) 2020-06-18
SG11201909718QA (en) 2019-11-28
HRP20211462T1 (hr) 2021-12-24
DK3615027T3 (da) 2021-08-30
HUE056485T2 (hu) 2022-02-28
EP3615027A1 (en) 2020-03-04
LT3615027T (lt) 2021-10-25
IL270066B1 (en) 2023-06-01
AU2018260390B2 (en) 2024-05-02
SI3615027T1 (sl) 2021-12-31
MD3615027T2 (ro) 2021-11-30
IL270066B2 (en) 2023-10-01
BR112019022331A2 (pt) 2020-05-26
JP2023022252A (ja) 2023-02-14
AU2018260390A1 (en) 2019-11-07
CY1124702T1 (el) 2022-07-22
CA3060390A1 (en) 2018-11-01
PT3615027T (pt) 2021-09-24
MA48459A (fr) 2020-03-04
EP3915557A1 (en) 2021-12-01
TW201902880A (zh) 2019-01-16
TWI821180B (zh) 2023-11-11
CN110662539A (zh) 2020-01-07
CN110662539B (zh) 2023-08-15
JP7225114B2 (ja) 2023-02-20
IL270066A (ru) 2019-12-31
ES2889100T3 (es) 2022-01-11
KR20190140005A (ko) 2019-12-18
EP3615027B1 (en) 2021-07-14
PL3615027T3 (pl) 2022-01-03
MA48459B1 (fr) 2021-09-30
MX2019012640A (es) 2020-12-11

Similar Documents

Publication Publication Date Title
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201892300A1 (ru) Макроциклические ингибиторы mcl1 для лечения рака
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
EA201991884A2 (ru) Ингибиторы g12c kras
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
EA201690752A1 (ru) Ингибиторы g12c kras
EA201591913A1 (ru) Ингибиторы протеинкиназы
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
UA111382C2 (uk) Інгібітори протеїнкінази
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
EA202193015A1 (ru) Ингибиторы cdk
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
CR20220548A (es) Compuestos de azalactama como inhibidores de hpk1